Dynamics of lymphokine production in HIV+ patients treated with HAART.
Int Conf AIDS 2000 Jul 9-14; 13:36 (abstract no.. LbPeA7016)
Cichutek K, Neumann J, Spielhofen A, Groeschel B, Miller V, Stazewski S, Doerr HW, Flory E Paul-Ehrlich-Institut, Dept. of Medical Biotechnology, Langen, Germany. Fax: +49 6103 77 12 55.
Identifying the immunologic and virologic consequences of anti-retroviral therapy in HIV-infected patients is of major importance in developing long-term treatment strategies for patients with HIV-infection. We designed a random trial to charaterize these immunological parameters after highly active anti-retroviral therapy (HAART) in patients who had prolonged viral suppression on anti-retroviral drugs (HAART Responders) or failed to respond on therapy (HAART Non-responders). Fourteen patients with viral loads f20 copies/microliter for > one year on HAART and ten HIV-infected patients with viral loads from 104 to 106 copies/microliter were enrolled in this study. IL-16, MIP-la, MIP-lb and RANTES production from sera of HIV-infected subjects as well as CD8+ lymphokine-producing cells, which were separated via positive selection from PBMCs, were evaluated by ELISA. In contrast to HAART Responders and seronegative control persons, activated CD8+ lymphocytes from HAART Non-responders revealed a significant increased Il-16 production (p= 0,0077) and also a higher release of MIP-1a (p= 0,338). In addition, sera concentration of MIP-1b (p= 0,0881) from HAART Non-responders was higher as compared to HAART Responders. Using the early activation marker CD69 in FACS analysis, production and release correlates with the activation status of CD8+ lymphocytes. These results indicate that the kinetic profile of lymphokine production may serve to define early markers for the efficiency of HAART.
Keywords: AEGIS, Antiretroviral Therapy, Highly Active, HIV Infections, Viral Load, CD8-Positive T-Lymphocytes, Lymphokines, HIV Seropositivity, RANTES, Interleukin-2, Human, Economics, AIDS 000709
LbPeA7016
